GT Biopharma Inc expected to post a loss of 8 cents a share - Earnings Preview
GT Biopharma Inc <GTBP.OQ> expected to post a loss of 8 cents a share - Earnings Preview
GT Biopharma Inc GTBP.OQ GTBP.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for GT Biopharma Inc is for a loss of 8 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GT Biopharma Inc is $3.00, about 837.2% above its last closing price of $0.32
This summary was machine generated August 10 at 21:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)